{"id":667607,"date":"2023-09-13T09:28:02","date_gmt":"2023-09-13T09:28:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=667607"},"modified":"2023-09-13T09:28:02","modified_gmt":"2023-09-13T09:28:02","slug":"dyslipidemia-market-is-expected-to-expand-at-a-healthy-growth-rate-during-the-forecast-period-20232032-key-companies-astrazeneca-novartis-gloxsosmithkline","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/dyslipidemia-market-is-expected-to-expand-at-a-healthy-growth-rate-during-the-forecast-period-20232032-key-companies-astrazeneca-novartis-gloxsosmithkline_667607.html","title":{"rendered":"Dyslipidemia  Market is Expected to Expand at a Healthy Growth Rate During the Forecast Period (2023-2032)| Key Companies &#8211; AstraZeneca, Novartis, Gloxsosmithkline"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/uploads\/1585648587.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Dyslipidemia  Market is Expected to Expand at a Healthy Growth Rate During the Forecast Period (2023-2032)| Key Companies - AstraZeneca, Novartis, Gloxsosmithkline \" src=\"https:\/\/www.abnewswire.com\/uploads\/1585648587.jpeg\" alt=\"Dyslipidemia  Market is Expected to Expand at a Healthy Growth Rate During the Forecast Period (2023-2032)| Key Companies - AstraZeneca, Novartis, Gloxsosmithkline \" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>DelveInsight Business Research LLP <\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">DelveInsight&#8217;s &#8220;Dyslipidemia Market Insights, Epidemiology, and Market Forecast-2032&#8221; report delivers an in-depth understanding of the Dyslipidemia, historical and forecasted epidemiology as well as the Dyslipidemia market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.<\/div>\n<p style=\"text-align: justify;\" dir=\"ltr\">DelveInsight&#8217;s &#8220;<strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/dyslipidemia-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=dpr\">Dyslipidemia Market Insights, Epidemiology, and Market Forecast-2032<\/a><\/strong>&#8221; report delivers an in-depth understanding of the Dyslipidemia, historical and forecasted epidemiology as well as the Dyslipidemia market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Key Highlights of the Dyslipidemia Market&nbsp;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">The Key Companies working in the Dyslipidemia market include Xention Ltd, Novartis, GlaxoSmithKline, AstraZeneca, Abbott and many others.&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">The Key Therapies working in the Dyslipidemia market include Metformin, Rosuvastatin, Atorvastatin, Pravastatin, and many others.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">&nbsp;<strong>Dyslipidemia&nbsp; Overview<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Dyslipidemia is the imbalance of lipids such as cholesterol, low-density lipoprotein cholesterol, (LDL-C), triglycerides, and high-density lipoprotein (HDL). This condition can result from diet, tobacco exposure, or genetics and can lead to cardiovascular disease with severe complications.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/uploads\/6b70ecf2813b2700abe7847fd0e7ed64.png\" alt=\"\" \/><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">&nbsp;<strong>Dyslipidemia&nbsp; Epidemiology Insights<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">The prevalence of dyslipidemia increases with age. In 2005-2008 an estimated 33.5% of U.S. adults older than 20 years of age had high LDL-C levels. Of these individuals with elevated LDL-C levels, only 48.1% received treatment, and 33.2% had their LDL-C controlled. The prevalence of LDL-C control seemed to be the lowest amongst individuals who were uninsured, Mexican American, or had income below the poverty level.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Click here to learn more about the <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/dyslipidemia-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=dpr\">Dyslipidemia&nbsp; Market Landscape<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>The Report Covers the Dyslipidemia&nbsp; Epidemiology Segmented by:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Dyslipidemia&nbsp; diagnosed cases&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Total Dyslipidemia&nbsp; incident cases<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Total Dyslipidemia&nbsp; prevalent cases&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Dyslipidemia&nbsp; treatment cases&nbsp;<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Dyslipidemia&nbsp; Market Outlook&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The Dyslipidemia market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Dyslipidemia market trends by analyzing the impact of current Dyslipidemia therapies on the market, unmet needs, drivers and barriers, and demand for better technology.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">This segment gives a thorough detail of the <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/dyslipidemia-market\">Dyslipidemia market trend of each marketed drug<\/a> and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Dyslipidemia market data are presented with relevant tables and graphs to give a clear view of the market at first sight.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">According to DelveInsight, the Dyslipidemia market in 7MM is expected to witness a major change in the study period 2019-2032.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Key Companies Working in the Dyslipidemia Market<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">AstraZeneca<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Xention Ltd<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Novartis Pharmaceuticals&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">GlaxoSmithKline<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">And many others<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Dyslipidemia&nbsp; Therapies Covered and Analyzed in the Report<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">&nbsp;<\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">GW856553<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">TA-8995<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Rosuvastatin<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Moxifloxacin<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">And many others&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">&nbsp;<strong>Learn more about the <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/dyslipidemia-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=dpr\">Key Companies and Emerging Therapies in the Dyslipidemia&nbsp; Market<\/a><\/strong><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Table of Contents&nbsp;<\/strong><\/p>\n<ol style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Key Insights&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Dyslipidemia&nbsp; Introduction&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Executive Summary of Dyslipidemia&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Disease Background and Overview<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Epidemiology and patient population<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Dyslipidemia&nbsp; Emerging Therapies<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Dyslipidemia&nbsp; Market Outlook<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Market Access and Reimbursement of Therapies<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Market Drivers&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Market Barriers&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Appendix<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Report Methodology<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">DelveInsight Capabilities<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Disclaimer<\/p>\n<\/li>\n<\/ol>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Learn about the detailed offerings of the report @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/dyslipidemia-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=dpr\">Dyslipidemia Market Outlook<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Adya Kaul<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=dyslipidemia-market-is-expected-to-expand-at-a-healthy-growth-rate-during-the-forecast-period-20232032-key-companies-astrazeneca-novartis-gloxsosmithkline\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 919650213330<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> Nevada<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/consulting\/due-diligence-services\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/consulting\/due-diligence-services<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/consulting\/due-diligence-services\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=dyslipidemia-market-is-expected-to-expand-at-a-healthy-growth-rate-during-the-forecast-period-20232032-key-companies-astrazeneca-novartis-gloxsosmithkline\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight Business Research LLP DelveInsight&#8217;s &#8220;Dyslipidemia Market Insights, Epidemiology, and Market Forecast-2032&#8221; report delivers an in-depth understanding of the Dyslipidemia, historical and forecasted epidemiology as well as the Dyslipidemia market trends in the United States, EU5 (Germany, Spain, Italy, France, &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/dyslipidemia-market-is-expected-to-expand-at-a-healthy-growth-rate-during-the-forecast-period-20232032-key-companies-astrazeneca-novartis-gloxsosmithkline_667607.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,417,406,404],"tags":[],"class_list":["post-667607","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/667607","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=667607"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/667607\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=667607"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=667607"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=667607"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}